Monoclonal antibodies are an effective treatment for COVID-19 if administered early in the course of disease (within 10 days of symptom onset). There are currently two products approved through the Food and Drug Administration through an Emergency Use Authorization (EUA). Due to emerging variants, some products may be restricted for use in certain states.
Home infusion providers are encouraged to participate in NHIA’s COVID-19 Home Infusion Therapy Program (C-HIT) by offering home infusion of COVID-19 monoclonal antibodies. As a participant in the program, NHIA will include the providers’ location and contact information on NHIA’s website and provider listing to help prescribers locate services for their patients. NHIA will also collect data on COVID-19 utilization and clinical outcomes to contribute to the scientific body of knowledge for effectiveness and safety of home infusion of these agents.
General Information for Home Infusion Providers
mAB Ordering and Teletracking
NHIA COVID-19 Home Infusion Therapy Program
Home infusion pharmacists and nurses are specially trained in providing a wide range of IV treatments in the home setting, including monoclonal antibodies. For more than 40 years, home infusion pharmacies have supported patients with conditions such as cancer, serious infections, autoimmune disorders, and GI disease. Home infusion providers coordinate with local nurses to administer home therapies and often have large service areas.
Physicians seeking to access home infusion for COVID-19 monoclonal antibody treatments are encouraged to directly contact a home infusion provider using the NHIA locator map. If you are unable to find a provider that serves your area, please send an email to Ryan Garst, PharmD, MBA, BCSCP at email@example.com for additional support.
General Information for Physicians